^
    Back
    Association details:
    Biomarker:EGFR E746_A750del
    Cancer:Non Small Cell Lung Cancer
    Drug:gefitinib (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Proc Natl Acad Sci U S A
    Title:

    EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

    Excerpt:
    Characteristics of patients sensitive to gefitinib (G) and erlotinib (E)....Four of the exon 19 deletion mutations were the same as the previously described del E746-A750….Deletion mutations in exon 19 of EGFR from NSCLCs sensitive to TKIs, gefitinib (G) or erlotinib (E).
    DOI:
    10.1073/pnas.0405220101
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Oncogene
    Title:

    Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants

    Excerpt:
    In different EGFR variant-expressing 32D cells, only cells harboring L858R, E746-A750 deletion, and G719S mutants were clearly more sensitive to gefitinib than wild-type EGFR-expressing cells. 
    DOI:
    10.1038/sj.onc.1209159